Hundreds of staff, employees, and community residents participated in heart-healthy activities throughout the Mount Sinai Health System, an annual effort in February, Heart Health Month, to educate individuals about the risk of cardiovascular disease.
An injectable nanoparticle that delivers HMG-CoA reductase inhibitors, or statins, which directly inhibit atherosclerotic plaque inflammation could represent a new frontier in the treatment of heart disease. This novel approach is being developed by researchers at Icahn School of Medicine at Mount Sinai, who have seen promising results in mice models and plan to translate their findings to humans within the next few years.
The Mount Sinai Hospital Cardiac Care Unit (CCU) was awarded a 2014 Beacon Award for Excellence from the American Association of Critical-Care Nurses (AACN), the leading society of acute- and critical-care nurses.
The Mount Sinai Hospital is one of three institutions in New York State, and one of one hundred in the nation, selected to study the safety and effectiveness of an implantable cranial nerve stimulation device for heart failure patients with debilitating fatigue, shortness of breath, and heart arrhythmias.
Mitral Valve Prolapse (MVP) is a common heart valve abnormality that affects up to 5 percent of the U.S. population. The mitral valve controls the flow of blood from the lungs to the main pumping chamber of the heart. MVP results from a degeneration of valve structure that leads to a regurgitation of blood backwards that can result in heart enlargement and weakening, as well as fatigue and shortness of breath.
What started as a casual observation among physicians almost a decade ago—that patients with HIV tend to develop hypertension and have a greater risk of heart attacks than the general population—has become a formal area of study and treatment within the Mount Sinai Health System.
Under the direction of Merle Myerson, MD, EdD, Director of the St. Luke’s Roosevelt Center for Cardiovascular Disease Prevention, and Director of the Cardiology Section of the Spencer Cox Center for Health, patients with HIV are being closely monitored and treated for heart disease and stroke. In fact, cardiovascular care has become increasingly critical to the overall health of HIV patients, as more of them live well into their 70s and 80s.
Interventional cardiologists at The Mount Sinai Hospital in October became the first in the world to use a new device to remove hard calcium buildup in a coronary artery in preparation for the placement of a stent to improve blood flow through the artery. The device, the Diamondback 360® Coronary Orbital Atherectomy System, was approved by the U.S. Food and Drug Administration one day before it was brought to Mount Sinai for use.
Since then, Mount Sinai’s cardiac catheterization team has performed more than 25 procedures under the leadership of Samin K. Sharma, MD, Director of Clinical and Interventional Cardiology at The Mount Sinai Hospital. Dr. Sharma says there have been no complications during or after the procedures.
Designer Pamella Roland’s spring 2013 collection took center stage in December at The Mount Sinai Medical Center’s Second Annual Women’s Health Fashion Show and Luncheon at The Waldorf=Astoria. The models wore jewelry provided by Chopard, and more than 500 guests enjoyed a luncheon menu selected by chef Mario Batali.
The event raised more than $450,000, which will be used to raise awareness about the importance of primary care in the prevention and detection of women’s medical issues, fund research on reproductive cancers, educate women about heart health, and investigate the relationship between gender differences and the environment.